Integrative Personal Omics Profiles during Periods of Weight Gain and Loss
Cell Systems, 2018
Piening B., Zhou W., Contrepois K., Röst H., Gu Urban G., Mishra T., Hanson B., Bautista E., Leopold S., Yeh C., Spakowicz D., Banerjee I., Chen C., Kukurba K., Perelman D., Craig C., Colbert E., Salins D., Rego S., Lee S., Zhang C., Wheeler J., Sailani M., Liang L., Abbott C., Gerstein M., Mardinoglu A., Smith U., Rubin D., Pitteri S., Sodergren E., McLaughlin T., Weinstock G., Snyder M.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Metabolic Diseases | Pathophysiology | Plasma |  Olink Target 96 |
Abstract
Advances in omics technologies now allow an unprecedented level of phenotyping for human diseases, including obesity, in which individual responses to excess weight are heterogeneous and unpredictable. To aid the development of better understanding of these phenotypes, we performed a controlled longitudinal weight perturbation study combining multiple omics strategies (genomics, transcriptomics, multiple proteomics assays, metabolomics, and microbiomics) during periods of weight gain and loss in humans. Results demonstrated that: (1) weight gain is associated with the activation of strong inflammatory and hypertrophic cardiomyopathy signatures in blood; (2) although weight loss reverses some changes, a number of signatures persist, indicative of long-term physiologic changes; (3) we observed omics signatures associated with insulin resistance that may serve as novel diagnostics; (4) specific biomolecules were highly individualized and stable in response to perturbations, potentially representing stable personalized markers. Most data are available open access and serve as a valuable resource for the community.